Today: 25 January 2026
Subscribe
Browse Category

NASDAQ:RVMD News 8 January 2026 - 12 January 2026

Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

New York, Jan 12, 2026, 11:17 EST — Regular session Shares of Revolution Medicines (RVMD) slipped around 1.8% to $116.51 in early Monday trading, pulling back from a 52-week peak amid fresh analyst notes following a rollercoaster week of takeover rumors. The stock fluctuated between $113.47 and $119.58 during the session, pegging the company’s market cap at about $23 billion.…
12 January 2026
····
Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

New York, January 11, 2026, 14:03 EST — Market closed. Merck & Co., Inc. shares closed down 0.4% on Friday at $110.53, and traders head into Monday with takeover chatter back in the tape. The Wall Street Journal reported Merck is in talks to buy Revolution Medicines in a deal valued around $28 billion to $32 billion. (The Wall Street…
11 January 2026
······
Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

New York, January 10, 2026, 20:11 EST — The market has closed. Revolution Medicines (RVMD.O) wrapped up Friday with a 10.7% gain, closing at $118.64. The cancer-drug developer remains in focus amid ongoing takeover buzz heading into next week. Shares fluctuated between $109.88 and $125.79, with roughly 20.8 million shares changing hands. Why this matters now: Dealmakers have flocked to…
11 January 2026
····
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

New York, Jan 10, 2026, 14:37 EST — Market closed Merck & Co (MRK) closed Friday 0.4% lower at $110.53 following reports that the pharmaceutical giant is negotiating to acquire cancer drug developer Revolution Medicines in a deal valued between $28 billion and $32 billion. (Reuters) Timing is crucial. As Merck faces patent losses on its blockbuster cancer drug Keytruda…
10 January 2026
·····
Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday

Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday

New York, January 10, 2026, 09:47 EST — Market closed Revolution Medicines shares jumped 10.7% to close at $118.64 on Friday, hitting a session high of $125.79 amid merger rumors. The Financial Times reported that Merck is negotiating a potential $28 billion to $32 billion acquisition of the biotech. (Financial Times) The timing matters. A deal with Revolution would give…
10 January 2026
····
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

New York, Jan 9, 2026, 20:01 (EST) — Market closed. Merck & Co (MRK.N) shares slipped on Friday following reports that the pharma giant is in talks to acquire cancer-focused biotech Revolution Medicines (RVMD.O) for as much as $32 billion. Merck ended the day down 0.4% at $110.53, after swinging between $110.26 and $112.46. (Reuters) The possible bid comes as…
10 January 2026
·····
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

New York, January 9, 2026, 17:15 ET — After-hours Revolution Medicines shares jumped 10.7% to $118.64 in after-hours trading on Friday, after the Financial Times reported Merck was in advanced talks to buy the cancer-drug developer for $28 billion to $32 billion. The stock swung between $109.88 and $125.79 in the session on volume of about 20.6 million shares. (Financial…
9 January 2026
·····
Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

New York, Jan 9, 2026, 13:59 EST — Regular session Shares of Revolution Medicines climbed on Friday as investors weighed a report that Merck is in talks to buy the cancer-drug developer for up to $32 billion. Revolution was up about 4.3% at $112.00, after touching $125.79 earlier in the session. (Reuters) The chatter matters because Merck is hunting for…
9 January 2026
····
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

New York, January 9, 2026, 12:09 EST — Regular session Merck & Co Inc shares were up about 0.4% at $111.41 on Friday as investors weighed a report that the drugmaker is in talks to buy cancer biotech Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped nearly 16% in extended trading on Thursday…
9 January 2026
·····
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

New York, January 8, 2026, 13:12 ET — Regular session AbbVie Inc shares fell on Thursday after the drugmaker denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge that will dent its 2025 profit outlook. AbbVie stock (ABBV) was down 3.7% at $224.84 at 1:12 p.m. ET, after swinging between $231.93 and $223.84. The decline takes…
8 January 2026
······
Revolution Medicines (RVMD) stock slips in premarket as AbbVie denies takeover talks, deal buzz lingers

Revolution Medicines (RVMD) stock slips in premarket as AbbVie denies takeover talks, deal buzz lingers

New York, Jan 8, 2026, 05:22 EST — Premarket Shares of Revolution Medicines fell 9.8% to $92.60 in premarket trading on Thursday, pulling back after a sharp, rumor-driven run-up in the prior session. Investing The whipsaw started after the Wall Street Journal reported AbbVie was in advanced discussions to buy the cancer-drug developer, a deal that could value Revolution at…
8 January 2026
···
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

New York, January 8, 2026, 05:14 (EST) — Premarket AbbVie Inc (ABBV) shares slipped 1.6% to about $229.64 in premarket trading on Thursday after the drugmaker denied it was in talks to buy cancer biotech Revolution Medicines and cut its 2025 profit view. Revolution’s stock fell 11.5% in extended trading after AbbVie’s statement, Reuters reported. Investing The whiplash matters because…
8 January 2026
·····
1 2

Stock Market Today

  • BillionToOne (BLLN) Shares Pull Back Amid Growth Prospects and Valuation Debate
    January 25, 2026, 7:59 AM EST. BillionToOne (BLLN) shares slipped 3.3% in one day, trading near $87.57, down 1.93% year-to-date. The diagnostics company shows 22.88% annual revenue growth but trades at a 45.31% discount to a $135.29 fair value estimate. Growth in noninvasive prenatal testing and a key Johnson & Johnson diagnostic partnership support optimism. However, increased competition in prenatal testing and potential reimbursement cuts pose risks. Investors are weighing whether the sell-off highlights a buying opportunity or reflects market caution about future growth. The firm's valuation rests on assumptions of revenue expansion, margin improvement, and evolving earnings.
Go toTop